Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018137293) THERAPEUTIC COMPOSITION FOR TREATING MESOTHELIN-POSITIVE TUMOR
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/137293 International Application No.: PCT/CN2017/081272
Publication Date: 02.08.2018 International Filing Date: 20.04.2017
IPC:
C12N 5/10 (2006.01) ,C12N 7/01 (2006.01) ,C12N 15/867 (2006.01) ,C12N 15/864 (2006.01) ,A61K 35/17 (2015.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10
Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7
Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01
Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79
Vectors or expression systems specially adapted for eukaryotic hosts
85
for animal cells
86
Viral vectors
867
Retroviral vectors
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79
Vectors or expression systems specially adapted for eukaryotic hosts
85
for animal cells
86
Viral vectors
864
Parvoviral vectors
[IPC code unknown for A61K 35/17]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
北京马力喏生物科技有限公司 BEIJING MARINO BIOTECHNOLOGY PTY LTD. [CN/CN]; 中国北京市 大兴区北京经济技术开发区科创六街88号院亦庄生物医药园A1-501室 Room A1-501, Biomedical Park In Yizhuang No.88 KeChuang 6th Street Beijing Development Area, Daxing Beijing 101111, CN
Inventors:
严勇朝 YAN, Yongchao; CN
朱益林 ZHU, Yilin; CN
陈思毅 CHEN, Siyi; CN
Agent:
北京清亦华知识产权代理事务所(普通合伙) TSINGYIHUA INTELLECTUAL PROPERTY LLC; 中国北京市 海淀区清华园清华大学照澜院商业楼301室 Room 301 Trade Building, Zhaolanyuan Tsinghua University, Qinghuayuan Haidian District, Beijing 100084, CN
Priority Data:
201710056392.725.01.2017CN
Title (EN) THERAPEUTIC COMPOSITION FOR TREATING MESOTHELIN-POSITIVE TUMOR
(FR) COMPOSITION THÉRAPEUTIQUE POUR LE TRAITEMENT D'UNE TUMEUR À MÉSOTHÉLINE POSITIVE
(ZH) 治疗间质素阳性肿瘤的治疗组合物
Abstract:
(EN) Provided are a transgenic lymphocyte, a construct, and a therapeutic composition for treating a cancer. A cell checkpoint of the transgenic lymphocyte is silenced, and the transgenic lymphocyte expresses a non-functional EGFR and a chimeric antigen receptor. The chimeric antigen receptor comprises an extracellular domain, and the extracellular domain comprises a heavy chain variable region and a light chain variable region of a single-chain antibody. The single-chain antibody specifically recognizes an antigen, mesothelin. The chimeric antigen receptor further comprises a transmembrane domain. The transmembrane domain is connected with the extracellular domain and is embedded in the membrane of the T lymphocyte. The chimeric antigen receptor further comprises an intracellular domain. The intracellular domain is connected with the transmembrane domain and comprises an intracellular segment of CD28 or 4-1BB and a CD3ζ chain.
(FR) La présente invention décrit un lymphocyte transgénique, un produit de recombinaison, et une composition thérapeutique pour le traitement d’un cancer. Un point de contrôle cellulaire du lymphocyte transgénique est inactivé, et le lymphocyte transgénique exprime un EGFR non fonctionnel et un récepteur antigénique chimérique. Le récepteur antigénique chimérique comprend un domaine extracellulaire, et le domaine extracellulaire comprend une région variable à chaîne lourde et une région variable à chaîne légère d'un anticorps monocaténaire. L'anticorps monocaténaire reconnaît spécifiquement un antigène, la mésothéline. Le récepteur antigénique chimérique comprend en outre un domaine transmembranaire. Le domaine transmembranaire est relié au domaine extracellulaire et est intégré dans la membrane du lymphocyte T. Le récepteur antigénique chimérique comprend en outre un domaine intracellulaire. Le domaine intracellulaire est relié au domaine transmembranaire et comprend un segment intracellulaire de CD28 ou 4-1 BB et une chaîne CD3ζ.
(ZH) 提供了一种转基因淋巴细胞、一种构建体和一种治疗癌症的治疗组合物,该转基因淋巴细胞的细胞检查点被沉默、表达无功能EGFR以及表达嵌合抗原受体,其中,该嵌合抗原受体包括:胞外区,胞外区包括单链抗体的重链可变区和轻链可变区,单链抗体特异性识别抗原间质素;跨膜区,跨膜区与所述胞外区相连,并且嵌入到所述T淋巴细胞的细胞膜中;胞内区,胞内区与所述跨膜区相连,并且该胞内区包括CD28或4-1BB的胞内段以及CD3ζ链。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)